Bausch Health Files 8-K: Agreement Termination, Officer Changes
Ticker: BHC · Form: 8-K · Filed: Aug 15, 2025 · CIK: 885590
Sentiment: neutral
Topics: agreement-termination, officer-changes, corporate-action
TL;DR
Bausch Health terminated a major deal and shuffled execs, filing an 8-K on Aug 14, 2025.
AI Summary
Bausch Health Companies Inc. filed an 8-K on August 15, 2025, reporting the termination of a material definitive agreement and changes in directors and officers. The filing also includes a Regulation FD disclosure and financial statements. The company was formerly known as Valeant Pharmaceuticals International, Inc., BioVail Corp, and BioVail Corp International.
Why It Matters
This filing signals significant corporate actions, including the end of a key agreement and potential shifts in leadership, which could impact the company's strategic direction and operational stability.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement and changes in officers can indicate underlying business challenges or strategic realignments that carry inherent risks.
Key Players & Entities
- Bausch Health Companies Inc. (company) — Registrant
- Valeant Pharmaceuticals International, Inc. (company) — Former company name
- BIOVAIL Corp (company) — Former company name
- BIOVAIL CORP INTERNATIONAL (company) — Former company name
- August 14, 2025 (date) — Date of earliest event reported
- August 15, 2025 (date) — Date of report
FAQ
What specific material definitive agreement was terminated by Bausch Health Companies Inc.?
The filing states the termination of a material definitive agreement but does not specify which agreement was terminated.
What were the reasons for the departure of directors or certain officers?
The filing indicates departures of directors or certain officers but does not provide the specific reasons for these changes.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 14, 2025.
What is the primary business of Bausch Health Companies Inc. according to the SIC code?
According to the Standard Industrial Classification code (2834), the primary business of Bausch Health Companies Inc. is Pharmaceutical Preparations.
What was Bausch Health Companies Inc. previously known as?
Bausch Health Companies Inc. was formerly known as Valeant Pharmaceuticals International, Inc., BIOVAIL Corp, and BIOVAIL CORP INTERNATIONAL.
Filing Stats: 786 words · 3 min read · ~3 pages · Grade level 10.4 · Accepted 2025-08-15 15:18:06
Filing Documents
- d858618d8k.htm (8-K) — 27KB
- d858618dex991.htm (EX-99.1) — 8KB
- g858618g0815214053793.jpg (GRAPHIC) — 3KB
- 0001193125-25-181736.txt ( ) — 154KB
- bhc-20250814.xsd (EX-101.SCH) — 2KB
- bhc-20250814_lab.xml (EX-101.LAB) — 18KB
- bhc-20250814_pre.xml (EX-101.PRE) — 11KB
- d858618d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit No. Description 99.1 Press release of the Company dated August 15, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL)]
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BAUSCH HEALTH COMPANIES INC. By: /s/ Seana Carson Name: Seana Carson Title: Executive Vice President, General Counsel Date: August 15, 2025